ICML 2017 | What we can look forward to in the world of non-Hodgkin lymphoma
Franco Cavalli, MD, FRCP, from the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland gives an overview of how therapies have progressed and what the future holds. The field of immunotherapy has made rapid progress, particularly CAR T-cell technology which in the past, had always been seen as too complex. Check-point inhibitors have already shown a high response rate in lymphomas and this data will only expand over the next year. Prof. Cavalli believes that precision medicine particularly in diffuse and follicular lymphoma will have more of a role. Ongoing technological advances will support PET guided treatment to move more to the forefront and expand into treating different types of Hodgkin lymphoma. This video was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
